ThermoGenesis (THMO) 10-Q 14 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 11, 2018
Document Information [Line Items]
Entity Registrant Name	CESCA THERAPEUTICS INC.
Entity Central Index Key	811,212
Trading Symbol	kool
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		11,482,480
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 2,872,000	$ 3,513,000
Accounts receivable, net of allowance for doubtful accounts of $277,000 ($274,000 at December 31, 2017)	1,549,000	1,687,000
Accounts receivable – related party	100,000	862,000
Inventories, net of reserves of $840,000 ($1,069,000 at December 31, 2017)	5,221,000	4,798,000
Prepaid expenses and other current assets	557,000	594,000
Total current assets	10,299,000	11,454,000
Restricted cash	1,000,000	1,000,000
Equipment, net	3,265,000	2,996,000
Goodwill	13,976,000	13,976,000
Intangible assets, net	21,590,000	21,629,000
Other assets	51,000	56,000
Total assets	50,181,000	51,111,000
Current liabilities:
Accounts payable	2,415,000	2,079,000
Accrued payroll and related expenses	441,000	532,000
Deferred revenue	722,000	384,000
Related party payable	606,000	606,000
Other current liabilities	2,211,000	1,863,000
Total current liabilities	6,395,000	5,464,000
Long-term debt-related party	7,200,000	6,700,000
Noncurrent deferred tax liability	4,730,000	4,730,000
Derivative obligations	338,000	597,000
Other non-current liabilities	398,000	408,000
Total liabilities	19,061,000	17,899,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 11,482,064 issued and outstanding (10,872,428 at December 31, 2017)	11,000	11,000
Paid in capital in excess of par	222,721,000	221,371,000
Accumulated deficit	(190,679,000)	(187,640,000)
Accumulated other comprehensive loss	(36,000)	(43,000)
Total Cesca Therapeutics Inc. stockholders’ equity	32,017,000	33,699,000
Noncontrolling interests	(897,000)	(487,000)
Total equity	31,120,000	33,212,000
Total liabilities and stockholders’ equity	$ 50,181,000	$ 51,111,000

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Accounts receivable, allowance for doubtful accounts	$ 227,000	$ 274,000
Inventories, reserves	$ 840,000	$ 1,069,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	11,482,064	10,872,428
Common stock, shares outstanding (in shares)	11,482,064	10,872,428

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Net revenues	$ 1,867,000	$ 3,252,000
Cost of revenues	1,515,000	1,875,000
Gross profit	352,000	1,377,000
Expenses:
Sales and marketing	325,000	335,000
Research and development	1,041,000	567,000
General and administrative	2,242,000	2,591,000
Total operating expenses	3,608,000	3,493,000
Loss from operations	(3,256,000)	(2,116,000)
Fair value change of derivative instruments	259,000	69,000
Interest expense	(361,000)	(19,000)
Other expenses	(12,000)	(31,000)
Net loss	(3,370,000)	(2,097,000)
Loss attributable to noncontrolling interests	(410,000)
Net loss attributable to common stockholders	(2,960,000)	(2,097,000)
Net loss	(3,370,000)	(2,097,000)
Other comprehensive income:
Foreign currency translation adjustments	7,000	(2,000)
Comprehensive loss	(3,363,000)	(2,099,000)
Comprehensive loss attributable to noncontrolling interests	(410,000)
Comprehensive loss attributable to common stockholders	$ (2,953,000)	$ (2,099,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.27)	$ (0.21)
Weighted average common shares outstanding – basic and diluted (in shares)	10,899,225	9,891,707

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (3,370,000)	$ (2,097,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	159,000	185,000
Stock based compensation expense	137,000	247,000
(Recovery of) reserve for excess and slow-moving inventories	(29,000)	22,000
Change in fair value of derivative	(259,000)	(69,000)
Loss on disposal of equipment		70,000
Net change in operating assets and liabilities:
Accounts receivable	896,000	75,000
Inventories	(224,000)	(211,000)
Prepaid expenses and other assets	39,000	(58,000)
Accounts payable	69,000	(150,000)
Related party payable		606,000
Accrued payroll and related expenses	(92,000)	(1,315,000)
Deferred revenue	259,000	286,000
Other current liabilities	356,000	(167,000)
Other noncurrent liabilities	5,000	33,000
Net cash used in operating activities	(2,054,000)	(2,543,000)
Cash flows from investing activities:
Capital expenditures	(290,000)	(33,000)
Net cash used in investing activities:	(290,000)	(33,000)
Cash flows from financing activities:
Payments on capital lease obligations	(9,000)	(23,000)
Proceeds from long-term debt-related party	500,000	1,500,000
Payment of financing cost		(13,000)
Proceeds from issuance of common stock, net	1,213,000
Net cash provided by financing activities	1,704,000	1,464,000
Effects of foreign currency rate changes on cash and cash equivalents	(1,000)	4,000
Net decrease in cash, cash equivalents and restricted cash	(641,000)	(1,108,000)
Cash, cash equivalents and restricted cash at beginning of period	4,513,000	4,899,000
Cash, cash equivalents and restricted cash at end of period	3,872,000	3,791,000
Supplemental non-cash financing and investing information:
Transfer of equipment to inventories	$ 172,000	$ 625,000

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Organization and Basis of Presentation Cesca Therapeutics Inc. (“Cesca Therapeutics,” “Cesca,” the “Company”), a Delaware corporation, is a regenerative medicine company that was founded in 1986 Cesca is an affiliate of the Boyalife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine. Liquidity and Going Concern The Company has a Revolving Credit Agreement (Credit Agreement) with Boyalife Asset Holding II, Inc. (Refer to Note 4 March 31, 2018, $7,200,000 $10,000,000 may On March 28, 2018, 609,636 $2.27 $1,213,000. At March 31, 2018, $2,872,000 $3,904,000. March 31, 2018 $190,679,000. one The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The condensed consolidated financial statements do not may Principles of Consolidation The condensed consolidated financial statements include the accounts of Cesca, its majority-owned subsidiary, ThermoGenesis, and its wholly-owned subsidiaries, TotipotentRX Cell Therapy, Pvt. Ltd. and TotipotentSC Scientific Product Pvt. Ltd. All significant intercompany accounts and transactions have been eliminated upon consolidation. Interim Reporting The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10 10 X. three March 31, 2018 not may December 31, 2018. 10 December 31, 2017.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Recently Adopted Accounting Standards On January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 not January 1, 2018. January 1, 2018 No. 2014 09, not 605 $79,000 January 1, 2018 606, 606 Revenue Recognition Revenue is recognized based on the five 606: Step 1 Step 2 not Step 3 Step 4 one Step 5 Disaggregation of Revenue The Company’s primary revenue streams include device sales, service revenue from device maintenance contracts and clinical services. Device Sales Device sales include devices and consumables for BioArchive, AXP, MXP, X not Service Revenue Service revenue consists primarily of maintenance contracts for BioArchive, AXP and X one two X one three not Clinical Services Service revenue in our Clinical Development Segment includes point of care procedures and cord blood processing and storage in our clinical segment. Point of care procedures are recognized when the procedures are performed. Cord blood processing and storage is recognized as the performance obligations are satisfied. Processing revenue is recognized when that performance obligation is completed immediately after the baby’s birth, with storage revenue recorded as deferred revenue and recognized ratably over time for up to 21 March 31, 2018, $285,000 may The following table summarizes the revenues of the Company’s reportable segments: Three Months Ended March 31, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 685,000 $ 65,000 $ 750,000 BioArchive 423,000 344,000 767,000 Manual Disposables 233,000 -- 233,000 Bone Marrow 38,000 -- 38,000 Other -- -- $ 17,000 17,000 Total Device Segment 1,379,000 409,000 17,000 1,805,000 Clinical Development Segment: Manual Disposables 22,000 -- -- 22,000 Bone Marrow -- 23,000 -- 23,000 Other -- 17,000 -- 17,000 Total Clinical Development 22,000 40,000 -- 62,000 Total $ 1,401,000 $ 449,000 $ 17,000 $ 1,867,000 Performance Obligations There is no no not may not Payments from domestic customers are normally due in two may 120 no Contract Balances The Company records a receivable when the title of goods have transferred, maintenance contracts have been fully executed or when services have been rendered. Generally, all sales are contract sales (with either an underlying contract or purchase order), resulting in all receivables being contract receivables. The company does not $252,000. $384,000 $722,000 March 31, 2018. Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2018 2019 2020 2021 2022 and After Total Service Revenue $ 716,000 $ 576,000 $ 133,000 $ 0 $ 0 $ 1,425,000 Clinical Revenue 9,000 15,000 15,000 15,000 231,000 285,000 Total $ 725,000 $ 591,000 $ 148,000 $ 15,000 $ 231,000 $ 1,710,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer and chief operating officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Clinical Development Division, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. ● The Device Division, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary. Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at March 31: 2018 2017 Vested Series A warrants 404,412 404,412 Unvested Series A warrants (1) 698,529 698,529 Warrants – other 4,030,600 3,725,782 Stock options 1,206,410 334,190 Restricted stock units 416 74,234 Total 6,340,367 5,237,147 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.

Note 3 - Acquisition of SynGen

Note 3 - Acquisition of SynGen	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. Acquisition of SynGen Inc. On July 7, 2017, The business acquired in the Transaction excludes certain assets and liabilities of SynGen that ThermoGenesis did not The acquisition was accounted for under the acquisition method of accounting for business combinations which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The consideration for the Transaction consisted of $1,000,000 2,000,000 20% $2,528,000. 2,000,000 first Supplemental Pro Forma Data The Company used the acquisition method of accounting to account for the SynGen acquisition and, accordingly, the results of SynGen are included in the Company’s consolidated financial statements for the period subsequent to the date of acquisition. For the three March 31, 2018, $31,000 three March 31, 2017 January 1, 2017. Three Months Ended March 31, 2017 Net revenues $ 3,380,000 Net loss $ (2,248,000 ) Basic and diluted net loss per common share $ (0.22 ) The unaudited pro forma financial information reflects certain adjustments related to the acquisition, such as the incremental amortization expense in connection with recording acquired identifiable intangible assets at fair value, the revised payroll expense associated with the new salaries of SynGen employees resulting from the merger, the elimination of SynGen expenses related to debt issuance costs, interest and other warrant related expenses, the elimination of the legal fees paid by both parties related to the litigation between Cesca and SynGen as ceasing the litigation was part of the Asset Acquisition Agreement and costs directly related to the acquisition.

Note 4 - Related Party Transact

Note 4 - Related Party Transactions	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	4 . Related Party Transactions Revolving Credit Agreement On March 6, 2017, $10,000,000 March 6, 2022 ( $7,200,000 March 31, 2018. The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% If the Note is not 90% 10 may not 19.99% June 22, 2018 The Credit Agreement was amended on April 16, 2018. 9. The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include a breach of the Loan documents, termination of operations, or bankruptcy. The Lender’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Credit Agreement continuing to be true at all times and there being no No The Company recorded interest expense of $360,000 $19,000 three March 31, 2018 2017, $1,017,000 $657,000 March 31, 2018 December 31, 2017, Distributo r Agreement On August 21, 2017, ® ® ® ® ® The term of the agreement is for three two Revenues During the three March 31, 2018 2017, $226,000 $0, Bill Payment Arrangement The Company entered into a bill payment arrangement whereby Boyalife Group Ltd. (Payor), the Company’s largest shareholder, agreed to pay the Company’s legal expenses payable to the Company’s attorney related to certain litigation involving SynGen (the “Bill Payment Arrangement”), although the Company remains jointly and severally liable for the payment of such legal fees. The terms of the Bill Payment Arrangement provided that the Company will reimburse Payor for any and all amounts paid by Payor in connection with the Bill Payment Arrangement under certain specified events. There is no March 31, 2018, $606,000

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	5 . Commitments and Contingencies Financial Covenants Effective May 15, 2017, one not $2,000,000. March 31, 2018. Warranty The Company offers a warranty on all of its non-disposable products of one two The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the three March 31, 2018 Balance at December 31, 2017 $ 291,000 Warranties issued during the period 18,000 Settlements made during the period (211,000 ) Changes in liability for pre-existing warranties during the period (1,000 ) Balance at March 31, 2018 $ 97,000 Contingen cies and Restricted Cash In fiscal 2016, May 4, 2017, $1,000,000 August 2016. October 2017, $1,000,000 no no March 31, 2018. In the normal course of operations, the Company may March 31, 2018, may not

Note 6 - Derivative Obligations

Note 6 - Derivative Obligations	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	6 . Derivative Obligation s Series A Warrants Series A warrants to purchase 404,412 June 30, 2016. Series A March 31, 2018 December 31, 2017 Market price of common stock $ 2.01 $ 3.00 Expected volatility 111% 107% Contractual term (years) 2.9 3.2 Discount rate 2.38% 1.99% Dividend rate 0% 0% Exercise price $ 8.00 $ 8.00 Expected volatilities are based on the historical volatility of the Company’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term. The Company recorded a gain of $259,000 $69,000 three March 31, 2018 2017, The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of March 31, 2018 December 31, 2017: Derivative Obligation March 31, 2018 December 31, 2017 Balance $ 338,000 $ 597,000 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ 338,000 $ 597,000 The following table reflects the change in fair value of the Company’s derivative liabilities for the three March 31, 2018: Amount Balance – December 31, 2017 $ 597,000 Change in fair value of derivative obligation 259,000 Balance – March 31, 2018 $ 338,000

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7 . Stockholders ’ Equity Common Stock On March 28, 2018, 609,636 $2.27 $171,000, $1,213,000. 304,818 $2.68 six 5.5 Stock Based Compensation The Company recorded stock-based compensation of $137,000 $247,000 three March 31, 2018 2017, The following is a summary of option activity for the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2017 1,156,027 $ 3.92 Granted 80,000 $ 3.00 Forfeited (2,435 ) $ 3.53 Expired (27,182 ) $ 4.67 Outstanding at March 31, 2018 1,206,410 $ 3.84 8.5 -- Vested and expected to vest at March 31, 2018 943,103 $ 4.07 8.3 -- Exercisable at March 31, 2018 306,582 $ 6.22 5.7 -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no three March 31, 2018. The fair value of the Company’s stock options granted for the three March 31, 2018 Expected life (years) 5.6 Risk-free interest rate 2.7 % Expected volatility 98 % Dividend yield 0 % Common Stock Restricted Units The following is a summary of restricted stock activity during the three March 31, 2018: Weighted Average Number of Shares Grant Date Fair Value Balance at December 31, 2017 416 $ 17.60 Granted -- Vested -- Forfeited -- Outstanding at March 31, 2018 416 $ 17.60 Warrants A summary of warrant activity for the three March 31, 2018 Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2017 4,828,723 $ 9.37 Warrants granted 304,818 2.68 Warrants canceled -- -- Warrants exercised -- -- Outstanding at March 31, 2018 5,133,541 $ 8.97 Exercisable at March 31, 2018 4,130,194 $ 9.60 At March 31, 2018, $0

Note 8 - Segment Reporting

Note 8 - Segment Reporting	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	8 . Segment Reporting The Company has two The Clinical Development Segment is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. The Device Segment is a pioneer and market leader in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The following table summarizes the operating results of the Company’s reportable segments: Three Months Ended March 31, 2018 Clinical Development Device Total Net revenues $ 62,000 $ 1,805,000 $ 1,867,000 Cost of revenues 71,000 1,444,000 1,515,000 Gross profit (9,000 ) 361,000 352,000 Operating expenses 1,179,000 2,429,000 3,608,000 Operating loss $ (1,188,000 ) $ (2,068,000 ) $ (3,256,000 ) Depreciation and amortization $ 68,000 $ 91,000 $ 159,000 Stock-based compensation expense $ 98,000 $ 39,000 $ 137,000 Goodwill $ 13,195,000 $ 781,000 $ 13,976,000 Total assets $ 38,941,000 $ 11,240,000 $ 50,181,000 Three Months Ended March 31, 2017 Clinical Development Device Total Net revenues $ 153,000 $ 3,099,000 $ 3,252,000 Cost of revenues 124,000 1,751,000 1,875,000 Gross profit 29,000 1,348,000 1,377,000 Operating expenses 1,934,000 1,559,000 3,493,000 Operating loss $ (1,905,000 ) $ (211,000 ) $ (2,116,000 ) Depreciation and amortization $ 116,000 $ 69,000 $ 185,000 Stock-based compensation expense $ 151,000 $ 96,000 $ 247,000

Note 9 - Subsequent Event

Note 9 - Subsequent Event	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	9 . S ubsequent Events On April 16, 2018, ● The Lender was granted the right to convert, at any time, outstanding principal and accrued but unpaid interest under the Credit Agreement into shares of Company common stock at a conversion price equal to $1.61 90% 10 April 2018 ● If the Company in the future issues shares of common stock, or is deemed to issue shares of common stock, prior to the full payment or conversion of the Amended Note for a price per share lower than the Fixed Conversion Price then in effect, the Fixed Conversion Price will be reduced to the price per share paid in the future issuance, with certain customary exceptions for equity plan issuances and issuances pursuant to certain strategic transactions. ● The Company has been granted the right to defer payment of the $657,000 December 31, 2017 December 31, 2018, $5.0 On May 7, 2018, No. 1 No. 1

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards On January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 not January 1, 2018. January 1, 2018 No. 2014 09, not 605 $79,000 January 1, 2018 606, 606
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606: Step 1 Step 2 not Step 3 Step 4 one Step 5 Disaggregation of Revenue The Company’s primary revenue streams include device sales, service revenue from device maintenance contracts and clinical services. Device Sales Device sales include devices and consumables for BioArchive, AXP, MXP, X not Service Revenue Service revenue consists primarily of maintenance contracts for BioArchive, AXP and X one two X one three not Clinical Services Service revenue in our Clinical Development Segment includes point of care procedures and cord blood processing and storage in our clinical segment. Point of care procedures are recognized when the procedures are performed. Cord blood processing and storage is recognized as the performance obligations are satisfied. Processing revenue is recognized when that performance obligation is completed immediately after the baby’s birth, with storage revenue recorded as deferred revenue and recognized ratably over time for up to 21 March 31, 2018, $285,000 may The following table summarizes the revenues of the Company’s reportable segments: Three Months Ended March 31, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 685,000 $ 65,000 $ 750,000 BioArchive 423,000 344,000 767,000 Manual Disposables 233,000 -- 233,000 Bone Marrow 38,000 -- 38,000 Other -- -- $ 17,000 17,000 Total Device Segment 1,379,000 409,000 17,000 1,805,000 Clinical Development Segment: Manual Disposables 22,000 -- -- 22,000 Bone Marrow -- 23,000 -- 23,000 Other -- 17,000 -- 17,000 Total Clinical Development 22,000 40,000 -- 62,000 Total $ 1,401,000 $ 449,000 $ 17,000 $ 1,867,000 Performance Obligations There is no no not may not Payments from domestic customers are normally due in two may 120 no Contract Balances The Company records a receivable when the title of goods have transferred, maintenance contracts have been fully executed or when services have been rendered. Generally, all sales are contract sales (with either an underlying contract or purchase order), resulting in all receivables being contract receivables. The company does not $252,000. $384,000 $722,000 March 31, 2018. Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2018 2019 2020 2021 2022 and After Total Service Revenue $ 716,000 $ 576,000 $ 133,000 $ 0 $ 0 $ 1,425,000 Clinical Revenue 9,000 15,000 15,000 15,000 231,000 285,000 Total $ 725,000 $ 591,000 $ 148,000 $ 15,000 $ 231,000 $ 1,710,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3
Segment Reporting, Policy [Policy Text Block]	Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer and chief operating officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Clinical Development Division, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. ● The Device Division, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at March 31: 2018 2017 Vested Series A warrants 404,412 404,412 Unvested Series A warrants (1) 698,529 698,529 Warrants – other 4,030,600 3,725,782 Stock options 1,206,410 334,190 Restricted stock units 416 74,234 Total 6,340,367 5,237,147 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.

Note 2 - Summary of Significa16

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 685,000 $ 65,000 $ 750,000 BioArchive 423,000 344,000 767,000 Manual Disposables 233,000 -- 233,000 Bone Marrow 38,000 -- 38,000 Other -- -- $ 17,000 17,000 Total Device Segment 1,379,000 409,000 17,000 1,805,000 Clinical Development Segment: Manual Disposables 22,000 -- -- 22,000 Bone Marrow -- 23,000 -- 23,000 Other -- 17,000 -- 17,000 Total Clinical Development 22,000 40,000 -- 62,000 Total $ 1,401,000 $ 449,000 $ 17,000 $ 1,867,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Remainder of 2018 2019 2020 2021 2022 and After Total Service Revenue $ 716,000 $ 576,000 $ 133,000 $ 0 $ 0 $ 1,425,000 Clinical Revenue 9,000 15,000 15,000 15,000 231,000 285,000 Total $ 725,000 $ 591,000 $ 148,000 $ 15,000 $ 231,000 $ 1,710,000
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2018 2017 Vested Series A warrants 404,412 404,412 Unvested Series A warrants (1) 698,529 698,529 Warrants – other 4,030,600 3,725,782 Stock options 1,206,410 334,190 Restricted stock units 416 74,234 Total 6,340,367 5,237,147

Note 3 - Acquisition of SynGen

Note 3 - Acquisition of SynGen (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Business Acquisition, Pro Forma Information [Table Text Block]	Three Months Ended March 31, 2017 Net revenues $ 3,380,000 Net loss $ (2,248,000 ) Basic and diluted net loss per common share $ (0.22 )

Note 5 - Commitments and Cont18

Note 5 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Balance at December 31, 2017 $ 291,000 Warranties issued during the period 18,000 Settlements made during the period (211,000 ) Changes in liability for pre-existing warranties during the period (1,000 ) Balance at March 31, 2018 $ 97,000

Note 6 - Derivative Obligatio19

Note 6 - Derivative Obligations (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Series A March 31, 2018 December 31, 2017 Market price of common stock $ 2.01 $ 3.00 Expected volatility 111% 107% Contractual term (years) 2.9 3.2 Discount rate 2.38% 1.99% Dividend rate 0% 0% Exercise price $ 8.00 $ 8.00
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Derivative Obligation March 31, 2018 December 31, 2017 Balance $ 338,000 $ 597,000 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ 338,000 $ 597,000
Derivative Instruments, Gain (Loss) [Table Text Block]	Amount Balance – December 31, 2017 $ 597,000 Change in fair value of derivative obligation 259,000 Balance – March 31, 2018 $ 338,000

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2017 1,156,027 $ 3.92 Granted 80,000 $ 3.00 Forfeited (2,435 ) $ 3.53 Expired (27,182 ) $ 4.67 Outstanding at March 31, 2018 1,206,410 $ 3.84 8.5 -- Vested and expected to vest at March 31, 2018 943,103 $ 4.07 8.3 -- Exercisable at March 31, 2018 306,582 $ 6.22 5.7 --
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Expected life (years) 5.6 Risk-free interest rate 2.7 % Expected volatility 98 % Dividend yield 0 %
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Weighted Average Number of Shares Grant Date Fair Value Balance at December 31, 2017 416 $ 17.60 Granted -- Vested -- Forfeited -- Outstanding at March 31, 2018 416 $ 17.60
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2017 4,828,723 $ 9.37 Warrants granted 304,818 2.68 Warrants canceled -- -- Warrants exercised -- -- Outstanding at March 31, 2018 5,133,541 $ 8.97 Exercisable at March 31, 2018 4,130,194 $ 9.60

Note 8 - Segment Reporting (Tab

Note 8 - Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Three Months Ended March 31, 2018 Clinical Development Device Total Net revenues $ 62,000 $ 1,805,000 $ 1,867,000 Cost of revenues 71,000 1,444,000 1,515,000 Gross profit (9,000 ) 361,000 352,000 Operating expenses 1,179,000 2,429,000 3,608,000 Operating loss $ (1,188,000 ) $ (2,068,000 ) $ (3,256,000 ) Depreciation and amortization $ 68,000 $ 91,000 $ 159,000 Stock-based compensation expense $ 98,000 $ 39,000 $ 137,000 Goodwill $ 13,195,000 $ 781,000 $ 13,976,000 Total assets $ 38,941,000 $ 11,240,000 $ 50,181,000 Three Months Ended March 31, 2017 Clinical Development Device Total Net revenues $ 153,000 $ 3,099,000 $ 3,252,000 Cost of revenues 124,000 1,751,000 1,875,000 Gross profit 29,000 1,348,000 1,377,000 Operating expenses 1,934,000 1,559,000 3,493,000 Operating loss $ (1,905,000 ) $ (211,000 ) $ (2,116,000 ) Depreciation and amortization $ 116,000 $ 69,000 $ 185,000 Stock-based compensation expense $ 151,000 $ 96,000 $ 247,000

Note 1 - Description of Busin22

Note 1 - Description of Business and Basis of Presentation (Details Textual) - USD ($)	Mar. 28, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Stock Issued During Period, Shares, New Issues	609,636
Shares Issued, Price Per Share	$ 2.27
Proceeds from Issuance of Common Stock, Net	$ 1,213,000	$ 1,213,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance		2,872,000		$ 3,513,000
Working Capital		3,904,000
Retained Earnings (Accumulated Deficit), Ending Balance		(190,679,000)		$ (187,640,000)
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Long-term Line of Credit, Total		7,200,000
Line of Credit Facility, Maximum Borrowing Capacity		$ 10,000,000

Note 2 - Summary of Significa23

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended
	Mar. 31, 2018USD ($)	Jan. 01, 2018USD ($)	Dec. 31, 2017USD ($)
Maximum Period Of Agreement	21 years
Contract with Customer, Liability, Revenue Recognized	$ 252,000
Contract with Customer, Liability, Current	$ 722,000		$ 384,000
Number of Reportable Segments	2
Retained Earnings [Member] | Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption		$ (79,000)

Note 2 - Summary of Significa24

Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Net revenues	$ 1,867,000	$ 3,252,000
Device [Member]
Net revenues	1,805,000
Device [Member] | AXP [Member]
Net revenues	750,000
Device [Member] | BioArchive [Member]
Net revenues	767,000
Device [Member] | Manual Disposables [Member]
Net revenues	233,000
Device [Member] | Bone Marrow [Member]
Net revenues	38,000
Device [Member] | Other Subsegments [Member]
Net revenues	17,000
Clinical Development [Member]
Net revenues	62,000
Clinical Development [Member] | Manual Disposables [Member]
Net revenues	22,000
Clinical Development [Member] | Bone Marrow [Member]
Net revenues	23,000
Clinical Development [Member] | Other Subsegments [Member]
Net revenues	17,000
Device Revenue [Member]
Net revenues	1,401,000
Device Revenue [Member] | Device [Member]
Net revenues	1,379,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	685,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	423,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	233,000
Device Revenue [Member] | Device [Member] | Bone Marrow [Member]
Net revenues	38,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Device Revenue [Member] | Clinical Development [Member]
Net revenues	22,000
Device Revenue [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues	22,000
Device Revenue [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues
Device Revenue [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues
Service [Member]
Net revenues	449,000
Service [Member] | Device [Member]
Net revenues	409,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	65,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	344,000
Service [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Device [Member] | Bone Marrow [Member]
Net revenues
Service [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Service [Member] | Clinical Development [Member]
Net revenues	40,000
Service [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues	23,000
Service [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues	17,000
Other [Member]
Net revenues	17,000
Other [Member] | Device [Member]
Net revenues	17,000
Other [Member] | Device [Member] | AXP [Member]
Net revenues
Other [Member] | Device [Member] | BioArchive [Member]
Net revenues
Other [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Device [Member] | Bone Marrow [Member]
Net revenues
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	17,000
Other [Member] | Clinical Development [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Mar. 31, 2018USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-04-01
Revenue	$ 725,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue	591,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue	148,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue	15,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue	231,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)
Revenue	1,710,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-04-01
Revenue	716,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue	576,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue	133,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue	0
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue	0
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)
Revenue	1,425,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-04-01
Revenue	9,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue	15,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue	15,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue	15,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue	231,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)
Revenue	$ 285,000

Note 2 - Summary of Significa26

Note 2 - Summary of Significant Accounting Policies - Calculation for Basic and Diluted Earnings Per Share (Details) - shares		3 Months Ended
		Mar. 31, 2018	Mar. 31, 2017
Anti-dilutive securities (in shares)		6,340,367	5,237,147
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)		404,412	404,412
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]	698,529	698,529
Warrant, Other [Member]
Anti-dilutive securities (in shares)		4,030,600	3,725,782
Employee Stock Option [Member]
Anti-dilutive securities (in shares)		1,206,410	334,190
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)		416	74,234
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 3 - Acquisition of SynGe27

Note 3 - Acquisition of SynGen (Details Textual) - SynGen [Member] - USD ($)	Jul. 07, 2017	Mar. 31, 2018
Payments to Acquire Businesses, Gross	$ 1,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,000,000
Percentage Of Common Stock Issued To Acquiree Shareholders	20.00%
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 2,528,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual		$ 31,000

Note 3 - Acquisition of SynGe28

Note 3 - Acquisition of SynGen - Supplemental Pro Forma Data (Details) - SynGen [Member]	3 Months Ended
	Mar. 31, 2017USD ($)$ / shares
Net revenues	$ 3,380,000
Net loss	$ (2,248,000)
Basic and diluted net loss per common share (in dollars per share) | $ / shares	$ (0.22)

Note 4 - Related Party Transa29

Note 4 - Related Party Transactions (Details Textual) - USD ($)	Aug. 21, 2017	Mar. 06, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Interest Expense, Total			$ 361,000	$ 19,000
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			10,000,000
Proceeds from Long-term Lines of Credit			7,200,000
Debt Instrument, Interest Rate, Stated Percentage		22.00%
Debt Instrument, Convertible, Percentage of Conversion Price		90.00%
Debt Instrument, Number of Trading Days Prior to the Maturity Date		10 days
Debt Instrument, Maximum Number of Shares Issued Upon Conversion, Percent		19.99%
Interest Expense, Total			360,000	19,000
Interest Payable			1,017,000		$ 657,000
Boyalife W.S.N. [Member]
Distributor Agreement Term	3 years
Distributor Agreement, Renewal Term	2 years
Boyalife Group Ltd. [Member]
Interest Payable			0
Revenue from Related Parties			226,000	$ 0
Due to Related Parties, Total			$ 606,000

Note 5 - Commitments and Cont30

Note 5 - Commitments and Contingencies (Details Textual) - USD ($)	May 04, 2017	Oct. 31, 2017	Mar. 31, 2018
Payment Terms, Severance Compensation			1 year
Short Term Investment Minimum			$ 2,000,000
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value	$ 1,000,000
Loss Contingency, Negotiation Condition Bond		$ 1,000,000
Loss Contingency Accrual, Ending Balance			$ 0
Minimum [Member]
Period Of Warranty On Products			1 year
Maximum [Member]
Period Of Warranty On Products			2 years

Note 5 - Commitments and Cont31

Note 5 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details)	3 Months Ended
	Mar. 31, 2018USD ($)
Balance at December 31, 2017	$ 291,000
Warranties issued during the period	18,000
Settlements made during the period	(211,000)
Changes in liability for pre-existing warranties during the period	(1,000)
Balance at March 31, 2018	$ 97,000

Note 6 - Derivative Obligatio32

Note 6 - Derivative Obligations (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Jun. 30, 2016
Class of Warrant or Right, Outstanding	5,133,541		4,828,723
Derivative, Gain (Loss) on Derivative, Net, Total	$ 259,000	$ 69,000
Series A Warrant [Member]
Class of Warrant or Right, Outstanding				404,412

Note 6 - Derivative Obligatio33

Note 6 - Derivative Obligations - Fair Value Assumptions (Details) - Series A Warrant [Member]	Mar. 31, 2018	Dec. 31, 2017
Measurement Input, Share Price [Member]
Valuation assumption	2.01	3
Measurement Input, Price Volatility [Member]
Valuation assumption	111	107
Measurement Input, Expected Term [Member]
Valuation assumption	2.9	3.2
Measurement Input, Discount Rate [Member]
Valuation assumption	2.38	1.99
Measurement Input, Expected Dividend Rate [Member]
Valuation assumption	0	0
Measurement Input, Exercise Price [Member]
Valuation assumption	8	8

Note 6 - Derivative Obligatio34

Note 6 - Derivative Obligations - Fair Value Hierarchy (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Derivative obligations	$ 338,000	$ 597,000
Fair Value, Inputs, Level 1 [Member]
Derivative obligations
Fair Value, Inputs, Level 2 [Member]
Derivative obligations
Fair Value, Inputs, Level 3 [Member]
Derivative obligations	$ 338,000	$ 597,000

Note 6 - Derivative Obligatio35

Note 6 - Derivative Obligations - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Balance	$ 597,000
Derivative, Gain (Loss) on Derivative, Net, Total	259,000	$ 69,000
Balance	$ 338,000

Note 7 - Stockholders' Equity36

Note 7 - Stockholders' Equity (Details Textual) - USD ($)	Mar. 28, 2018	Mar. 31, 2018	Mar. 31, 2017
Stock Issued During Period, Shares, New Issues	609,636
Shares Issued, Price Per Share	$ 2.27
Payments of Stock Issuance Costs	$ 171,000
Proceeds from Issuance of Common Stock, Net	$ 1,213,000	$ 1,213,000
Allocated Share-based Compensation Expense, Total		$ 137,000	$ 247,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		0
Class of Warrant or Right, Outstanding, Intrinsic Value		$ 0
Class of Warrant or Right, Exercisable, Intrinsic Value		$ 0
Warrants Issused in Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	304,818
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.68
Warrants and Rights Outstanding, Term	5 years 182 days

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details)	3 Months Ended
	Mar. 31, 2018USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	1,156,027
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 3.92
Granted, options (in shares) | shares	80,000
Granted, weighted average exercise price, options (in dollars per share) | $ / shares	$ 3
Forfeited (in shares) | shares	(2,435)
Forfeited (in dollars per share) | $ / shares	$ 3.53
Expired, options (in shares) | shares	(27,182)
Expired, weighted average exercise price, options (in dollars per share) | $ / shares	$ 4.67
Outstanding, options (in shares) | shares	1,206,410
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 3.84
Outstanding, weighted average remaining contractual life, options (Year)	8 years 182 days
Outstanding, aggregate intrinsic value, options | $
Vested and Expected to Vest, options (in shares) | shares	943,103
Vested and Expected to Vest, weighted average exercise price, options (in dollars per share) | $ / shares	$ 4.07
Vested and Expected to Vest, weighted average remaining contractual life, options (Year)	8 years 109 days
Vested and Expected to Vest, aggregate intrinsic value, options | $
Exercisable, options (in shares) | shares	306,582
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 6.22
Exercisable, weighted average remaining contractual life, options (Year)	5 years 255 days
Exercisable, aggregate intrinsic value, options | $

Note 7 - Stockholders' Equity38

Note 7 - Stockholders' Equity - Schedule of Assumptions (Details)	3 Months Ended
	Mar. 31, 2018
Expected life (years) (Year)	5 years 219 days
Risk-free interest rate	2.70%
Expected volatility	98.00%
Dividend yield	0.00%

Note 7 - Stockholders' Equity39

Note 7 - Stockholders' Equity - Restricted Stock Unit Activity Granted to Employees (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Balance, Number of Shares (in shares) | shares	416
Balance, Weighted Average Grant Date Fair Value, (in dollars per share) | $ / shares	$ 17.60
Granted, Number of Shares (in shares) | shares
Granted, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares
Vested, Number of Shares (in shares) | shares
Vested, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares
Forfeited, Number of Shares (in shares) | shares
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares
Balance, Number of Shares (in shares) | shares	416
Balance, Weighted Average Grant Date Fair Value, (in dollars per share) | $ / shares	$ 17.60

Note 7 - Stockholders' Equity40

Note 7 - Stockholders' Equity - Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Balance (in shares) | shares	4,828,723
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 9.37
Warrants granted (in shares) | shares	304,818
Warrants granted, weighted average exercise price (in dollars per share) | $ / shares	$ 2.68
Warrants exercised (in shares) | shares
Warrants exercised (cashless), weighted average exercise price (in dollars per share) | $ / shares
Balance (in shares) | shares	5,133,541
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 8.97
Exercisable at March 31, 2018 (in shares) | shares	4,130,194
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 9.60

Note 8 - Segment Reporting (Det

Note 8 - Segment Reporting (Details Textual)	3 Months Ended
	Mar. 31, 2018
Number of Reportable Segments	2
Number of Operating Segments	2

Note 8 - Segment Reporting - Su

Note 8 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Net revenues	$ 1,867,000	$ 3,252,000
Cost of revenues	1,515,000	1,875,000
Gross profit	352,000	1,377,000
Operating expenses	3,608,000	3,493,000
Operating loss	(3,256,000)	(2,116,000)
Depreciation and amortization	159,000	185,000
Stock-based compensation expense	137,000	247,000
Goodwill	13,976,000		$ 13,976,000
Total assets	50,181,000		$ 51,111,000
Operating loss	(3,256,000)	(2,116,000)
Clinical Development [Member]
Net revenues	62,000
Clinical Development [Member] | Operating Segments [Member]
Net revenues	62,000	153,000
Cost of revenues	71,000	124,000
Gross profit	(9,000)	29,000
Operating expenses	1,179,000	1,934,000
Operating loss	(1,188,000)	(1,905,000)
Depreciation and amortization	68,000	116,000
Stock-based compensation expense	98,000	151,000
Goodwill	13,195,000
Total assets	38,941,000
Operating loss	(1,188,000)	(1,905,000)
Device [Member]
Net revenues	1,805,000
Device [Member] | Operating Segments [Member]
Net revenues	1,805,000	3,099,000
Cost of revenues	1,444,000	1,751,000
Gross profit	361,000	1,348,000
Operating expenses	2,429,000	1,559,000
Operating loss	(2,068,000)	(211,000)
Depreciation and amortization	91,000	69,000
Stock-based compensation expense	39,000	96,000
Goodwill	781,000
Total assets	11,240,000
Operating loss	$ (2,068,000)	$ (211,000)

Note 9 - Subsequent Event (Deta

Note 9 - Subsequent Event (Details Textual) - USD ($)	Apr. 16, 2018	Mar. 31, 2018	Dec. 31, 2017
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Interest Payable		$ 1,017,000	$ 657,000
Subsequent Event [Member] | Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Interest Payable	$ 657,000
Convertible Debt [Member] | Amended Note [Member] | Subsequent Event [Member]
Debt Instrument, Convertible, Conversion Price	$ 1.61
Debt Instrument, Convertible, Conversion Price, Percent of Weighted Average Common Stock Price	90.00%